ResourceSpectroscopy

Quantification of Crystallinity Using Transmission Raman Spectroscopy

26 Feb 2019

The crystallinity of an active pharmaceutical ingredient (API) may affect its bio‑availability and its overall patient efficacy. It is critical to be able to measure the crystalline content of a final drug product. Transmission Raman spectroscopy (TRS) can differentiate and quantify crystalline and amorphous API. Measurements are fast, and the transmission sampling geometry ensures that the signal obtained is representative of the bulk, and not biased to the surface

TRS100 Quantitative Pharmaceutical Analysis System

Agilent Technologies

The TRS100 enables fast, easy-to-use whole tablet or capsule content uniformity and polymorph screening for pharmaceutical finished-product testing and formulation development. Easier to implement than other spectroscopic methods, Agilent's transmission Raman spectroscopy (TRS) technology allows simple method development and deployment for quantitative analysis in quality control applications.

(4)

Links

Tags